Biotron's Phase 2 Trial Confirms BIT225 HIV Treatment Potential

Biotron (ASX: BIT) has received further indications that its lead antiviral drug BIT225 is a potential candidate for the treatment of issues related to HIV.

Small CapsJun 18 22:03 ET

Biotron Meets Primary Objectives of Phase Two HIV Trial; Shares Surge 25%

Biotron (ASX:BIT) met the primary objectives of its phase two trial investigating the use of the BIT225-010 inhibitor in combination with antiretroviral therapy in patients with human immunodeficiency

MT NewswiresApr 4 21:35 ET

Stocks of the Hour: Linius Technologies, Biotron, Elixir Energy

To register for today's webinar click here.Linius Technologies Ltd (ASX:LNU) has signed a second US college conference and its first deployment in American football. The agreement is to provide its Wh

sharecafeApr 4 20:43 ET

Biotron Secures Nearly AU$2 Million R&D Tax Rebate in Fiscal 2023

Biotron (ASX:BIT) secured AU$1.65 million rebate for the fiscal year ended June 30, 2023, from the Australian government's research and development tax incentive scheme, the drug development firm said

MT NewswiresFeb 8 00:46 ET

Biotron Completes Dosing Segment of Phase Two COVID-19 Clinical Trial

Biotron (ASX:BIT) completed the dosing segment for its phase two clinical trial investigating the use of the antiviral medication BIT225 in patients with COVID-19. The trial aims to determine if the m

MT NewswiresAug 16, 2023 03:55 ET

Biotron (ASX:BIT) Kicks off Phase II COVID-19 Clinical Trial in Thailand

The Market HeraldMay 3, 2023 22:37 ET